RECHERCHE

A prospective, multicenter and randomized comparison of the Hydrus TM to the IStent, in order to reduce intraocular pressure in what is known as primary open- angle glaucoma.

GOAL

Compare the new Hydrus implant to the iStent 's capacity (the standard implant) to reduce the pressure in the eye.

A randomized, prospective, and multi-center trial comparing the safety and efficiency of the Hydrus implant, meant to reduce intraocular pressure in patients with glaucoma or undergoing cataract surgery.

GOAL

The goal of this study is to determine if the Hydrus IVANTIS implant can be implanted safely in the eye and reduce pressure following cataract removal and an intraocular lens (IOL) has been implanted in the eye.

A 12-month randomized, double-blind, active-controlled, parallel-group, multicenter study to compare the safety of AR-13324 Ophthalmic Solution at 0.02% BID with that of a Timolol maleate ophthalmic solution at 0.5% BID for patients with high intraocular pressure.

GOAL

The goal of this study is to compare the safety of ophthalmic solution AR13324 at 0.02% with that of an ophthalmic solution of 0.5% timolol maleate, available on the market to lower intraocular pressure in patients with glaucoma or ocular hypertension (increased ocular pressure).

Efficiency and safety of sustained-release Bimatoprost in patients affected by open-angle glaucoma or ocular hypertension.

GOAL

The purpose of this study was to examine the safety (safety of use) and effectiveness of two different amounts (10 μg and 15 μg) of sustained-release Bimatoprost, compared to eye drops containing Timolol at 0.5% to reduce ocular pressure in patients with glaucoma or high ocular pressure. 0.5% Timolol is an approved drug for lowering ocular pressure. Bimatoprost SR is a very small implant, which is biodegradable (dissolves naturally in the body) and contains Bimatoprost. The sustained release Bimatoprost is placed inside a chamber of the eye (between the cornea [the transparent part of the eye] and the iris [the coloured part of the eye]).

Additive effect of the therapeutic combination of fixed-dose 1% brinzolamide and 0.2% brimonidine, administered twice daily as an adjunct to a prostaglandin analogue.

OBJECTIF

Demonstrate the ability of a fixed-dose SIMBRINZA combination therapy to reduce intraocular pressure in study participants also treated with a prostaglandin analogue such as TRAVATAN 0.004%, LUMIGAN® 0.01%, or XALATAN® 0.005%, relatively to the effect and capacity of treatment with a prostaglandin analogue used alone to reduce intraocular pressure.